Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Advanced Prostate Cancer
100%
Second-generation Antiandrogens
100%
MDV3100
100%
Prostate Cancer
66%
Androgen Receptor
66%
Mouse Model
33%
Prostate-specific Antigen
33%
Serum Concentration
33%
DNA Binding
33%
Phase III Clinical Trial
33%
Relative Affinity
33%
Tumor Regression
33%
Nuclear Translocation
33%
Patient Progress
33%
Castration-resistant Prostate Cancer
33%
Coactivator
33%
Antiandrogen
33%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
33%
Androgen Receptor Expression
33%
Bicalutamide
33%
Castration-resistant
33%
Nonsteroidal Antiandrogens
33%
Androgen Action
33%
Androgen Response Element
33%
Medicine and Dentistry
Prostate Cancer
100%
Antiandrogen
100%
Androgen Receptor
60%
Enzalutamide
60%
Androgen
40%
Biological Marker
20%
Clinical Trial
20%
Prostate Specific Antigen
20%
Receptor Expression
20%
Tumor Regression
20%
DNA Binding
20%
DNA Responsive Element
20%
Castration Resistant Prostate Cancer
20%
Bicalutamide
20%
Blood Group A Antigen
20%
Diseases
20%
Pharmacology, Toxicology and Pharmaceutical Science
Prostate Cancer
100%
Antiandrogen
100%
Androgen Receptor
60%
Enzalutamide
60%
Androgen
40%
Clinical Trial
20%
Biological Marker
20%
Mouse Model
20%
Prostate Specific Antigen
20%
Tumor Regression
20%
Castration Resistant Prostate Cancer
20%
Bicalutamide
20%
Blood Group A Antigen
20%
Diseases
20%
Biochemistry, Genetics and Molecular Biology
Androgen Receptor
100%
Enzalutamide
100%
Mouse Model
33%
Clinical Trial
33%
Blood Level
33%
DNA Binding
33%
Prostate-Specific Antigen
33%
Response Element
33%
Blood Group A Antigen
33%
Bicalutamide
33%